



00114353A

**United States Patent** [19]

[11] **Patent Number:** 6,114,353

**Margolin**

[45] **Date of Patent:** Sep. 5, 2000

[54] **COMPOSITIONS AND METHOD FOR  
TREATMENT OF LYMPHOMAS,  
LEUKEMIAS, AND LEIOMYOMAS**

[76] **Inventor:** Solomon B. Margolin, 6723 Desco Dr.,  
Dallas, Tex. 75225

[21] **Appl. No.:** 09/239,211

[22] **Filed:** Jan. 28, 1999

**Related U.S. Application Data**

[63] Continuation-in-part of application No. 09/162,011, Sep. 28, 1998, which is a continuation-in-part of application No. 08/913,202, Sep. 3, 1997, abandoned, which is a continuation-in-part of application No. PCT/US96/02737, Mar. 4, 1996, which is a continuation-in-part of application No. 08/397,962, Mar. 3, 1995, abandoned.

[51] **Int. Cl.<sup>7</sup>** ..... A61K 31/44; A61K 31/47

[52] **U.S. Cl.** ..... 514/313; 514/334; 514/336;  
514/341; 514/342; 514/345

[58] **Field of Search** ..... 514/345, 342,  
514/341, 336, 313, 334

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

4,042,699 8/1977 Gadekar ..... 514/345  
4,052,509 10/1977 Gadekar ..... 514/345

*Primary Examiner*—Jerome D. Goldberg  
*Attorney, Agent, or Firm*—John H. Crozier

[57] **ABSTRACT**

In a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidenced by their low toxicity, and molecular actions. Such drugs include as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s). The compositions of this invention are novel as anti-neoplastic drugs, namely as an agent for treating leukemias, lymphomas, and leiomyomas.

**4 Claims, 4 Drawing Sheets**

3C406 U.S. PTO  
09/724378  
11/27/00



002227-324260